Calcifediol (known active substance with new data exclusivity: secondary hyperparathyroidism in chronic renal failure)

Subject:

• Active Substance: Calcifediol
• Name: Rayaldee^®
• Therapeutic area: Secondary hyperparathyreoidism in chronic renal failure
• Pharmaceutical company: Fresenius Medical Care Nephrologica Deutschland GmbH

Time table:

• Start: 01.02.2022
• Final decision by G-BA: 21.07.2022

No additional benefit proved:

• No additional benefit proved